← SEC 公告列表 | SPRO SEC 公告 | Spero Therapeutics, Inc.（SPRO）

重大事件 即時報告 8-K 2026-06-25

Spero Therapeutics 於 2026 年 6 月 23 日舉行股東年會，並提交 8-K 表格披露多項經股東批准的決議

於 SEC 網站開啟原文

AI 繁中摘要

Spero Therapeutics 於 2026 年 6 月 23 日舉行股東年會，並提交 8-K 表格披露多項經股東批准的決議 🗳️ **重點一：擴大股本授權** 股東通過修訂公司章程，將普通股授權發行總數由 1.2 億股大幅增至 2.4 億股，並已於同日向德拉瓦州州務卿存檔生效。 **重點二：通過 2026 年股票激勵計劃** 新計劃獲批，最多可發行 12,895,866 股普通股，用於未來員工、董事及顧問的股權獎勵。此舉將為公司提供更靈活的薪酬工具，但亦可能導致現有股東權益被攤薄 🧩 **重點三：董事選舉與其他投票** - 兩名 Class III 董事候選人 Milind Deshpande 博士及 Kathleen Tregoning 成功連任，任期至 2029 年年會。 - 股東以壓倒性票數批准 PricewaterhouseCoopers LLP 為 2026 財年核數師。 - 關於高層管理人員薪酬的諮詢投票亦獲通過（贊成 27,890,254 票 vs 反對 1,002,982 票）。 **對投資者的潛在影響** 該 8-K 主要反映公司治理層面的變動：授權股份倍增及新激勵計劃為未來融資、併購或人才留任鋪路，短期內不會直接影響營運業績，但投資者需關注潛在的股本稀釋風險 📉 年會出席率約 70.91%，投票結果顯示管理層提案獲得廣泛支持。
展開英文正文 
8-K

 false 0001701108 --12-31 0001701108 2026-06-23 2026-06-23 
  
  
 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
  
  

 FORM 8-K
  
  

 CURRENT REPORT
 Pursuant to Section 13 or 15(d)
 of The Securities Exchange Act of 1934
 Date of Report (Date of earliest event reported): June 23, 2026
  
  

 SPERO THERAPEUTICS, INC. 
 (Exact name of registrant as specified in its charter)
  
  

  

Delaware
 
001-38266
 
46-4590683

 (State or other jurisdiction
 of incorporation)

 
 (Commission
 File Number)

 
(I.R.S. Employer
Identification No.)
  

 675 Massachusetts Avenue, 14th Floor
 Cambridge, Massachusetts

 
02139

(Address of principal executive offices)
 
(Zip Code)
 Registrant’s telephone number, including area code (857) 242-1600
  
  

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  

☐
 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  

☐
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  

☐
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

☐
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 Securities registered pursuant to Section 12(b) of the Act:
  

 Title of each class

 
 Trading
Symbol(s)

 
 Name of each exchange
on which registered

Common Stock, $0.001 par value
 
SPRO
 
The Nasdaq Global Select Market
 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 Emerging growth company ☐
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  
  
  

 

Item 5.02
 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 

 Approval of the 2026 Stock Incentive Plan 
 At the 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Spero Therapeutics, Inc. (the “Company”) held on June 23, 2026, the Company’s stockholders approved the Spero Therapeutics, Inc. 2026 Stock Incentive Plan (the “2026 Plan”), which had previously been adopted by the Company’s board of directors (the “Board”), subject to stockholder approval. Subject to adjustments in accordance with the 2026 Plan, up to 12,895,866 shares of common stock may be issued from time to time pursuant to the 2026 Plan. 
 The description of the 2026 Plan is contained on pages 49 to 59 of the Company’s proxy statement for the Annual Meeting (the “Proxy Statement”), filed with the Securities and Exchange Commission (the “SEC”) on April 27, 2026, is incorporated herein by reference. A complete copy of the 2026 Plan is attached hereto as Exhibit 99.1 and is incorporated herein by reference. 
  

Item 5.03
 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. 

 Amendment to Articles of Incorporation 
 At the Annual Meeting, the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation, to increase the total number of shares of common stock authorized for issuance thereunder from 120,000,000 shares to 240,000,000 shares. The certificate of amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) was filed with the Secretary of State of the State of Delaware on June 23, 2026 and became effective upon filing. 
 The foregoing description is qualified in its entirety by the Certificate of Amendment, which is attached as Exhibit 3.1 and is incorporated herein by reference. 
  

Item 5.07
 Submission of Matters to a Vote of Stockholders 

 On June 23, 2026, the Company held its Annual Meeting. Of the 57,901,493 shares of common stock issued and outstanding and eligible to vote as of the record date of April 24, 2026, a quorum of 41,061,190 shares, or approximately 70.91% of the outstanding shares, were present in person or by proxy at the Annual Meeting. 
 The following actions were taken at the Annual Meeting: 
  

 
1.
 The following nominees were reelected to serve on the Company’s board of directors as Class III directors until the Company’s 2029 annual meeting of stockholders, based on the following votes: 

  

 Name

  
Votes For
 
  
Votes Withheld
 
  
Broker Non-Votes
 

 Milind Deshpande, Ph.D.

  
 
26,745,670
 
  
 
2,254,740
 
  
 
12,060,780
 

 Kathleen Tregoning

  
 
28,259,925
 
  
 
740,485
 
  
 
12,060,780
 

  

 
2.
 The selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, based on the following votes: 

  

 Votes For

  
 Votes Against

  
 Votes Abstained

  
 Broker Non-Votes

40,866,196
  
189,300
  
5,694
  
N/A

  

 
3.
 The advisory vote on the compensation of the Company’s named executive officers, as described in the Proxy Statement, was approved, based on the following votes: 

  

 Votes For

  
 Votes Against

  
 Votes Abstained

  
 Broker Non-Votes

27,890,254
  
1,002,982
  
107,174
  
12,060,780

  

 
4.
 The amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the total number of shares of common stock authorized for issuance thereunder from 120,000,000 shares to 240,000,000 shares, was approved, based on the following votes: 

  

 Votes For

  
 Votes Against

  
 Votes Abstained

  
 Broker Non-Votes

30,356,780
  
10,558,645
  
145,765
  
N/A

  

 
5.
 The Spero Therapeutics, Inc. 2026 Stock Incentive Plan, was approved, based on the following votes: 

  

 Votes For

  
 Votes Against

  
 Votes Abstained

  
 Broker Non-Votes

25,379,610
  
3,567,416
  
53,384
  
12,060,780

  

 

Item 9.01
 Financial Statements and Exhibits 

  

(d)
 Exhibits 

  

 Exhibit No.

  
 Description

3.1
  
Certificate of Amendment to Restated Certificate of Incorporation of Spero Therapeutics, Inc. 

99.1
  
Spero Therapeutics, Inc. 2026 Stock Incentive Plan (incorporated by reference to Exhibit 99.1 of registrant’s Registration Statement on Form S-8 (File No. 333-296972) filed with the SEC on June 23, 2026)

104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)

  

 

 SIGNATURE 
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
  

Date: June 25, 2026
 

 
SPERO THERAPEUTICS, INC.

 

 
By:
 
 /s/ Esther Rajavelu

 

 

 
Esther Rajavelu

 

 

 
Chief Executive Officer and Chief Financial Officer